Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nightingale OTC trading in the US likely to start already within a week

By Antti LuiroHead of Nordic ER Development, Analyst
Nightingale Health

Translation: Original published in Finnish on 3/18/2025 at 7:12 am EET.

Nightingale announced last week that it had submitted an application for a transfer to the main list and yesterday the company announced that the listing prospectus for its transfer to the Main Market of Nasdaq Helsinki has been approved by the Finnish Financial Supervisory Authority. Trading in the company’s shares is expected to transfer to the Main Market tomorrow, on Wednesday, March 19.

Nightingale also announced yesterday the establishment of an ADR program in the US and that it expects trading in its B shares and ADRs to begin between March 19 and March 24 on the OTCQX Market in the US. ADRs are depositary receipts representing foreign shares and can be traded in US dollars. According to the release, they are specially designed to make it easier for American investors to purchase, hold and sell non-US securities.

We commented last week that we thought it was very likely that the company would apply for an OTC listing after the main listing later in the spring. The news on the progress of the OTC listing is therefore expected, although OTC trading will start sooner than expected after the move to the main list. The news has no impact on our view of the stock and we commented more extensively on this earlier in November here.

Login required

This content is only available for logged in users

Create account

Nightingale Health

3.48EUR17.3.2025 klo 19.00
2.90EURTarget price
Accumulate
Recommendation updated:07.03.

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures07.03.

202425e26e
Revenue4.45.28.2
growth-%4.2 %19.2 %58.2 %
EBIT (adj.)-18.6-17.3-16.2
EBIT-% (adj.)-426.6 %-332.6 %-197.1 %
EPS (adj.)-0.29-0.27-0.25
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.
Forum discussions
Tutkimuspuolen uutuutta: Nightingalelta voi tilata nykyisen metaboliikan lisäksi samasta näytteestä proteomiikka-analyysin research.nightingalehealth...
22 hours ago
by Monsieur
11
Kiinnostava uutinen, tässä kommenttia! Inderes Nightingale teki Suomessa tärkeän päänavauksen julkiselle sektorille - Inderes Näemme yhteisty...
yesterday
by Antti Luiro
29
Suomessahan jos/kun tämmöinen sisäänajetaan julkiselle ei paluuta oo. Vaikka firma painaisi tappiota seuraavat 10 vuotta löytyy jostain julkista...
yesterday
by Cle
1
Nightingale Healthin teknologia käyttöön Suomen julkisessa terveydenhuollossa " Lisäksi Inderesin analyytikko Antti Luiro arvioi, että yhtiö...
yesterday
by Hapzu
1
Tämä on nyt SE uutinen, mitä olen odottanut. Nyt löytyy uskoa testiin, kun julkinen puoli sen hyväksyy. Peli on nyt avattu oikeasti.
yesterday
by Maikki
10
Luovuin osakkeistani muutama kuukausi sitten 2,75, nyt takaisin alle 3 eurolla. Usko palautui sopimuksen myötä. Muut hyvinvointialueet tulevat...
yesterday
by Umpi
10
NGH (eikä näköjään kukaan muukaan heidän puolestaan) ei ole vielä tuonut tätä uutista Twitteriin. Löytyisi kyllä lontooksikin Globally unique...
yesterday
by Hapzu
7
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.